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Introduction
The CLC and CLF-1 constitute the two subunits of the heterodimeric cytokine CLC:CLF-1 [1] [2] [3] . For cellular signal induction, CLC:CLF-1 first targets the CNTFRα, its primary and GPI-anchored receptor, to form a membrane-bound trimeric complex. The CLC:CLF-1:CNTFRα complex subsequently recruits gp130/LIFRβ which mediates transmembrane signaling via the Janus Kinase/Signal Transducers and Activators of Transcription 3 (JAK/STAT3) pathway 4 . Mice deficient in any of the three subunits display one and the same phenotype and die within 24 h after birth due to a reduced number of facial neurons and insufficient suckling [5] [6] [7] [8] . Findings in humans likewise underscore the functional coherence of the three subunits. Thus, human mutations (homozygote or compound) causing dysfunction of CLC:CLF-1 or CNTFRα, all result in the socalled cold-induced sweating/Crisponi syndrome, a condition characterized by symptoms such as impaired suckling and swallowing, various dysmorphic features, temperature spikes, and paradoxical and perfuse sweating at low temperatures [9] [10] [11] .
In vitro, the combination of CLC and CNTFRα is both necessary and sufficient for interaction with gp130/LIFRβ and the induction of signaling in cells 12 . The role of CLF-1 on the other hand is less clear. It is not directly involved in signaling, and has long been regarded as an appendix that mainly serves to facilitate the cellular secretion of CLC 1 . However, recent findings show that CLF-1 has additional and more important functions implicating both the signaling and turnover of CLC and CNTFRα. Thus, it appears that CLF-1 contains three independent binding sites: one for its well-known binding to CLC; one that mediates direct binding to the CNTFRα; and a third (high affinity) site for interaction with the endocytic receptor sorLA. As both CLC and CLF-1 seem to target CNTFRα with a considerable lower affinity than the CLC:CLF-1 complex, it is conceivable that CLF-1 (via its CNTFRα-binding site) promotes the unification of CLC and CNTFRα and thereby facilitates signaling 13 .
CLF-1's interaction with sorLA, the main issue of the present presentation, plays a completely different role. SorLA is one of the five type 1 receptors that constitute the Vps10p-domain receptor family 14 . It is expressed in a variety of tissues but in particular in brain and neuronal tissues 15 . Similar to the other family members sorLA carries an N-terminal ligand binding Vps10p-domain, but in addition, it also comprises other domain types including ligand-binding elements found in members of the low-density lipoprotein receptor family 15 . Its cytoplasmic tail interacts with several adaptor proteins, e.g., adaptor protein-1 and -2, and sorLA conveys efficient endocytosis as well as intracellular sorting and transport of bound proteins [16] [17] [18] . The Vps10p-domain comprises a large ten-bladed β-propeller 19, 20 , which binds a series of unrelated ligands including CLF-1 (but notably, not CLC) 13 . The binding site in CLF-1 is accessible even after complex formation with CLC and CNTFRα which means that sorLA binds not only free CLF-1, but also CLC:CLF-1 and the trimeric complex CLC:CLF-1:CNTFRα CLF-1 and CLC:CLF-1, but these are soluble proteins whereas CNTFRα is fixed to the surface membrane by a GPI-anchor. The question is therefore if binding of CLC:CLF-1:CNTFRα allows sorLA to internalize the entire complex and thereby to alter the surface-membrane expression of CNTFRα (and the subsequent cellular susceptibility to CLC:CLF-1 signal induction), and/or the turnover of CNTFRα.
The experiments described in the present report were designed to clarify the following questions: Does sorLA mediate CLC:CLF-1-dependent downregulation of surface-membrane CNTFRα? To clarify this, it was initially tried to determine the turnover of CNTFRα (in the absence and presence of sorLA) by means of metabolic labeling and pulse-chase experiments as described in 21 . However, attempts to label CNTFRα using a mixture of [S 35 ] cysteine and [S 35 ] methionine showed poor incorporation of radioactivity. This suggested a very low degree of new-synthesis, which in all probability would be unable to compensate for a sudden and significant loss of receptors. To determine if CNTFRα was downregulated when interconnected via CLC:CLF-1 to sorLA, it was therefore decided simply to measure (using Western blotting) the total cellular pool of CNTFRα before and after exposure to CLC:CLF-1 -and to compare results in cells transfected or not transfected with sorLA.
Does sorLA target CNTFRα to lysosomes? To answer this question, the localization of CNTFRα -internalized via its CLC:CLF-1-mediated binding to sorLA -was examined using immunocytochemistry, and labeling with antibodies directed towards CNTFRα and the late-endosome/ lysosome marker Lysosomal- shown in Figure 1 . Culture the cells in Dulbecco Modified Eagle´s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin (full medium) in a 5% carbon dioxide incubator at 37 ˚C. 3. Wait until the cells are 50 -80% confluent. 4. Remove the medium from the wells, wash once with Dulbecco Phosphate Buffered Saline (DPBS), and add fresh full medium with or without (control) 10 nM CLC:CLF-1 as indicated in Figure 1 . Incubate the cells at 37 ˚C. 5. After 0 and 5 h of incubation, recover the medium and store it at 4 ˚C in 1.5 mL tubes. Then add 1% Triton X-100 lysis buffer (20 mM TrisHCl, 10 mM EDTA, pH 8.0) supplemented with a proteinase inhibitor cocktail to each well (1 min, 4 ˚C). Subsequently, transfer the cell lysates to 1.5 mL tubes (4 ˚C). 6. Spin the tubes containing the medium and cell lysate (3,000 x g, 3 min, 4 ˚C) and transfer the supernatants to 1.5 mL tubes (4 ˚C). Discard the pellet. Transfer 5 μL of each cell lysate supernatant to new 1.5 mL tubes -use them to measure the protein content later (step 1.7). Immediately, add nonreducing LDS sample buffer to all the supernatants and vortex the samples. 7. Use the 5 μL aliquots to measure the protein content in the cell lysate supernatants using a commercial protein assay according to manufacturer's protocol. 8. Heat the samples at 95 ˚C for 5 min. 9. Subject an equal amount of protein from each sample to reducing SDS-PAGE 13 and Western blotting 13 and visualize the content of sorLA, β-actin, and CNTFRα-Myc in the medium and in the cell lysates using rabbit anti-sorLA 16 (5 μg/mL), mouse anti-β-actin (0.4 μg/mL), and mouse anti-Myc (1 μg/mL) antibodies and the appropriate HRP-linked secondary antibodies (1:2,000). 10. Quantify the bands by densitometry according to manufacturer's protocol. Caution: Paraformaldehyde is highly toxic, avoid contact with skin, eyes, and mucous. Gloves and safety glasses should be worn and solutions made inside a fume hood. 6. Wash the cells once in PBS and permeabilize the cells for 5 min at RT in saponin diluted in PBS (0.5% saponin). 7. Dilute goat anti-CNTFRα (1 μg/mL) (notably not the mouse anti-Myc used for Western blotting) and mouse anti-LAMP-1 (15 μg/mL) antibodies in 0.5% saponin and incubate the cells with the antibodies for 2 h at RT.
Immunocytochemistry in Combination with Lysosomal Inhibitors
8. Wash the cells 4x (5 min) in 0.5% saponin and incubate the cells with donkey anti-goat Alexa 488-and donkey anti-mouse Alexa 568-conjugated secondary antibodies (6 μg/mL) for 2 h at RT. 9. Wash the cells 4x (5 min) in 0.5% saponin, twice in deionized water (1 min), and mount the cover slides on microscope slides using mounting media. 10. Analyze the antibody-staining of the cells by confocal microscopy using a laser-scanning confocal microscope with a 63X C-apochromat water immersion objective, NA 1.2.
Western Blot-detection of the pSTAT3 Level
1. Seed HEK293-sorLA cells (which express endogenous levels of CNTFRα) in a 4-well plate as shown in Figure 3 . Culture the cells in full medium as above. 2. Wait until the cells are 50 -80% confluent. 3. Remove the medium from the wells, wash once in PBS, and add fresh full medium with or without 10 nM CLC:CLF-1 to the cells as indicated in Figure 3 . Incubate the cells at 37 ˚C for 5 h. 4. Remove the medium, wash the cells twice in unsupplemented DMEM (blank medium; without FBS and antibiotics), and then reincubate the cells for 90 min (37 ˚C) in blank medium. 5. Once again, remove the medium and add fresh blank medium with or without 5 nM CLC:CLF-1 (to initiate STAT3 phosphorylation) as indicated in Figure 3 . Incubate for 15 min at 37 ˚C. 6. Quickly remove the medium and lyse the cells (1 min, 4 ˚C) by adding 1% Triton X-100 lysis buffer (20 mM Tris-HCl, 10 mM EDTA, pH 8.0) supplemented with a proteinase inhibitor cocktail and a phosphatase inhibitor cocktail to each well. Subsequently, transfer the cell lysates to 1.5 mL tubes (4 ˚C). 7. Transfer 5 μL of each supernatant to new 1.5 mL tubes -use them to measure the protein content later (step 3.8). Immediately, add nonreducing LDS sample buffer to all the supernatants and vortex the samples. 8. Measure the protein content of the 5 μL aliquots using a commercial protein assay according to manufacturer's protocol. 9. Sonicate each sample at RT until they are no longer viscous (approximately 1 min) and subsequently heat them at 95 ˚C for 5 min. 10. Subject an equal amount of protein from each sample to SDS-PAGE 13 and Western blotting 13 and visualize the content of pSTAT3 and total STAT3 in the cell lysates using rabbit anti-pSTAT3 (1:2000) and mouse anti-STAT3 (1:1,000) antibodies and the appropriate HRP-linked mouse and rabbit secondary antibodies (1:2,000). 11. Quantify the bands by densitometry according to manufacturer's protocol. Figure 1 shows a schematic representation of the cell-seeding and CLC:CLF-1 incubation in protocol 1. Figure 2 shows a schematic representation of the cell-seeding and leu/pep and CLC:CLF-1 incubation in protocol 2. Figure 3 shows a schematic representation of the cellseeding and CLC:CLF-1 incubation and stimulation in protocol 3. Figure 4 shows the sorLA-mediated CLC:CLF-1-dependent downregulation of CNTFRα. Figure 5 shows the sorLA-mediated endocytosis and lysosomal targeting of CNTFRα. Figure 6 shows the lower response to CLC:CLF-1 stimulation after CNTFRα downregulation.
Representative Results
Note that bands signifying CNTFRα-Myc have similar density at time zero, whereas downregulation of CNTFRα-Myc is demonstrated by the weaker band in sorLA transfectants after 5 h (Figure 4) . Figure 5 shows that CNTFRα-Myc has accumulated in LAMP-1 positive vesicles of leu/pep treated cells. In contrast, no accumulation of CNTFRα-Myc is seen in cells not subjected to leu/pep treatment. This demonstrates that CNTFRα-Myc is sorted to lysosomes and degraded. As can be seen in Figure 6 , the level of pSTAT3 is significantly reduced in pre-stimulated cells as compared to the level in cells that has not been exposed to CLC:CLF-1. This is in accordance with the observed sorLA-mediated downregulation of CNTFRα in the pre-stimulated cells (Figure 4 ). . Please click here to view a larger version of this figure.
Discussion
The protocol described here can be used specifically to demonstrate the sorLA-mediated CLC:CLF-1-dependent downregulation and lysosomal targeting of CNTFRα, as well as the accompanying weakened response to CLC:CLF-1 stimulation.
The HEK293 cell line is well-suited for this protocol, as they have only a minor endogenous expression of CNTFRα and sorLA, are easy to transfect, express gp130/LIFRβ, and have a large cell body, which is suited for immunocytochemistry. However, in theory any cell line with similar properties should work as well.
The protocol has two critical steps. The first concerns step 2.3, in which the leu/pep medium must be replaced approximately every 6 h for 24 h. Failure to do so may result in active lysosomal enzymes and less or no detectable accumulation of protein in the lysosomes. The second critical step (3.4) concerns washing upon pre-incubation with CLC:CLF-1. It is important to remove any unbound ligand, and to allow the cells time to recover (avoiding continued stimulation) in unsupplemented DMEM (blank medium). This will ensure a low background level of pSTAT3 during the subsequent re-stimulation with CLC:CLF-1 (step 3.5).
Notably, Figure 6 demonstrates that the cellular response (pSTAT3) decreases in parallel with the sorLA-mediated downregulation of CNTFRα. It should be emphasized however, that although a reduced response is in accordance with (and to be expected upon) a reduction of the CNTFRα pool, it does not prove that the low CNTFRα expression alone accounts for the reduced cellular response. Thus, changes -resulting from prestimulation or transfection -in any of the functional elements of the signaling pathway upstream to pSTAT3 may have contributed to the altered response.
The basic concept of the protocol is not limited to this particular receptor system. By modifying the protocol (i.e. another cell line, other antibodies, other ligands, etc.) it can be used to determine the ligand-induced downregulation of other receptors as well -regardless of sorLA´s involvement. However, it should be noted that analysis of receptor-downregulation by Western blotting is mainly suited for receptors, e.g., GPIanchored receptors, which exhibit a slow turnover and a low degree of new synthesis in unstimulated cells. Thus, in receptors showing a high level of new-synthesis, ligand-induced downregulation may be compensated for by synthesis of new receptors. Under these circumstances, the downregulation of the receptor pool can instead be determined by means of metabolic labeling and pulse-chase experiments as described in 21 . Alternatively, iodinated antibodies (preferably Fc-fragments) that do not interfere with receptor binding can be used to "tag" the ectodomain of the receptor, and the expected downregulation can then be determined by radioactive counting of cell pellet and medium.
For logistic reasons we transfected our cells with a CNTFRα construct carrying a Myc-tag, and in the present protocol a mouse anti-Myc antibody was used for Western blot-detection of the receptor. In contrast, a goat anti-CNTFRα antibody was used for immunocytochemistry and double labeling as LAMP-1 was detected by a mouse antibody -and obviously use of two primary mouse antibodies would result in unspecific (overlapping) staining with secondary antibodies. Note that since the goat anti-CNTFRα also works in Western blotting (not shown), the protocol could easily be modified and applied to cells transfected with untagged CNTFRα.
Finally, it has recently been shown that also the endocytic receptor sortilin binds CLC:CLF-1 with high affinity 22 . Thus, it is conceivable that sortilin, like sorLA, interconnects to CLC:CNTFRα via CLF-1 and is able to mediate endocytosis and lysosomal targeting of CNTFRα as well. Using sortilin instead of sorLA, the present protocol may be used to clarify this question.
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